Teva UK Limited Launches Generic Valsartan and Valsartan HCTZ

CASTLEFORD, England, November 15, 2011 -

We are pleased to announce the day-one launch of generic Valsartan tablets and capsules, and Valsartan Hydrochlorothiazide (HCTZ) tablets.

Valsartan is a generic version of Diovan^® (Valsartan) and Valsartan HCTZ is the generic version Co-Diovan^® (Valsartan HCTZ); both from Novartis.  They are indicated in the treatments of Heart failure, Hypertension and Recent myocardial infarction.  

Valsartan and Valsartan HCTZ are available immediately in the award-winning Teva 360 livery. The strengths and presentations are as follows:

                                                                   Teva

      Product      Strength     Pack Size      Indication      retail price
                                          Hypertension, Recent
                                               myocardial
                                           infarction, Heart
     Valsartan   40mg tablets       7           failure          GBP1.22

                                              Hypertension
     Valsartan   320mg tablets     28                            GBP7.08
                                          Hypertension, Recent
                                               myocardial
                                           infarction, Heart
     Valsartan   40mg capsules     28           failure          GBP7.68
                                          Hypertension, Recent
                                               myocardial
                                           infarction, Heart
     Valsartan   80mg capsules     28           failure          GBP7.68
                                          Hypertension, Recent
                                               myocardial
                                           infarction, Heart
     Valsartan  160mg capsules     28           failure          GBP10.13
                                               Essential
     Valsartan   80mg /12.5mg               hypertension in
       HCTZ         tablets        28            adults          GBP4.89
                                               Essential
     Valsartan   160mg /12.5mg              hypertension in
       HCTZ         tablets        28            adults          GBP6.44
                                               Essential
     Valsartan    160mg /25mg               hypertension in
       HCTZ         tablets        28            adults          GBP6.44

Kim Innes, Commercial Director at Teva said: “As the leading generics company in the country and with the widest portfolio of our competitors, Teva continues with strong product launches and patent expiries.   We’ve already launched 19 products this year including now eight day one patent expiries, in a variety of strengths and pack sizes.

“It’s good for Pharmacy, because patent expiries provide them with the opportunities for increasing margins and keeping costs down.  But, importantly, it also means that we continue to do our bit in saving the NHS over £7bn a year.”

New or existing customers can order through their local Teva Territory Sales Manager, by completing the online form, or calling on 0800-085-8621

To find out more about Teva UK Limited, visit www.tevauk.com.

Notes to Editors:

About Teva UK Limited

Teva UK Limited is one of the UK’s top ten pharmaceutical manufacturers, with a presence in the generics, branded respiratory and hospitals markets. It has the widest range of any UK generic pharmaceutical company and markets solid and liquid dose, injectable and respiratory medicines to healthcare professionals. The company is part of Teva Pharmaceutical Industries Ltd.

About Teva Pharmaceutical Industries Ltd

Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world’s largest generic drug maker, with a global product portfolio of more than 1,450 molecules and a direct presence in 60 countries. Teva’s branded businesses focus on neurological, respiratory and women’s health therapeutic areas as well as biologics. Teva’s leading innovative product, Copaxone^®, is the number one prescribed treatment for multiple sclerosis. Teva employs approximately 40,000 people around the world and reached $16.1 billion in net sales in 2010.

For media enquiries, contact the Teva UK Limited Communications team on +44(0)1977-628500, or email media.enquiries@tevauk.com.

.